Secondary hypertension: Obesity and the metabolic syndrome

Journal of Clinical Hypertension

Volumn 10, Issue 7, 2008, Pages 567-574

  Singer, Gregory M ^a   Setaro, John F ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LEPTIN; LOSARTAN; NORADRENALIN; RENIN INHIBITOR; SIBUTRAMINE; SODIUM; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; VERAPAMIL;

ADRENERGIC SYSTEM; AEROBIC EXERCISE; BARIATRIC SURGERY; BLOOD PRESSURE REGULATION; CALORIC RESTRICTION; CLINICAL TRIAL; DRUG RESPONSE; GLUCOSE INTOLERANCE; HEART OUTPUT; HEMODYNAMICS; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY TUBULE ABSORPTION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; METABOLIC SYNDROME X; MULTIDRUG RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NORADRENALIN BLOOD LEVEL; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; SLEEP APNEA SYNDROME; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TARGET ORGAN; VASOCONSTRICTION; VASODILATATION; WEIGHT GAIN; WEIGHT REDUCTION; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECT; METABOLISM; RISK REDUCTION;

ANTIHYPERTENSIVE AGENTS; BARIATRIC SURGERY; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HEMODYNAMICS; HUMANS; HYPERTENSION; LEPTIN; METABOLIC SYNDROME X; OBESITY; RENIN-ANGIOTENSIN SYSTEM; RISK REDUCTION BEHAVIOR; SYMPATHETIC NERVOUS SYSTEM; WEIGHT LOSS;

EID: 54449088450     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.08178.x     Document Type: Review

References (75)

1. Stamler J. Epidemiologic findings on body mass and blood pressure in adults. Ann Epidemiol. 1991;1:347-362.
2. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults 1999-2000. JAMA. 2002;288:1723-1727.
3. Dyer AR, Elliott P, Shipley M. Body mass index versus height and weight in relation to blood pressure. Finding for the 10,079 persons in the INTERSALT Study. Am J Epidemiol. 1990;131:589-596.
4. Garrison RJ, Kannel WB, Stokes J, et al. Incidence and precursors of hypertension in young adults: The Framingham Offspring Study. Prev Med. 1987;16:235-251.
5. Rosamond W, Flegal K, Friday G, et al. Heart Disease and Stroke Statistics-2007 Update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115(5):e69-e171.
6. Ogden CL, Carroll MD, Curin LR, et al. Prevalence of overweight and obesity in the United States 1999-2004. JAMA. 2006;295:1549-1555.
7. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Third Report (Adult Treatment Panel II, Final Report). Circulation. 2002;106:3142-3421.
8. Li C, Ford ES, McGuire LC, et al. Increasing trends in waist circumference and abdominal obesity among US adults. Obesity (Silver Spring). 2007;15:216-224.
9. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care. 2004;27:2444-2449.
10. Wong ND, Pio JR, Franklin SS, et al. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol. 2003;91:1421-1426.
11. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206.
12. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-79.
13. Din-Dzietham R, Liu Y, Bielo MV, et al. High blood pressure trends in children and adolescents in national surveys 1963-2002. Circulation. 2007;116:1488-1496.
14. Gelber RP, Gaziano JM, Manson JE, et al. A prospective study of body mass index and the risk of developing hypertension in men. Am J Hypertens. 2007;20:370-377.
15. Isaksson H, Cederholm T, Jansson E, et al. Therapy resistant hypertension associated with central obesity, insulin resistance, and large muscle fibre area. Blood Press. 1993;2:46-52.
16. Hall WD. Resistant hypertension, secondary hypertension, and hypertensive crises. Cardiol Clin. 2002;20:281-289.
17. Hernández-delRey R, Armario P, Martin-Baranera M, et al. Target-organ damage and cardiovascular risk profile in resistant hypertension: Influence of the white-coat effect. Blood Press Monit. 1998;3:331-337.
18. Bramlage P, Pittrow D, Wittchen HU, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004;17:904-910.
19. Garg JP, Elliott WJ, Folker A, et al. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens. 2005;18:619-626.
20. Martell N, Rodgriguez-Cerillo M, Grobbee DE, et al. High prevalence of secondary hypertension and insulin resistance in patients with refractory hypertension. Blood Press. 2003;12:149-154.
21. Modan M, Almog S, Fuchs Z, et al. Obesity, glucose intolerance, hyperinsulinemia, and response to antihypertensive drugs. Hypertension. 1991;17:565-573.
22. Moser M, Setaro JF. Resistant or difficult to control hypertension. N Engl J Med. 2006;355:385-392.
23. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:2560-2572.
24. Player MS, Mainous AG 3rd, Diaz VA, et al. Prehypertension and insulin resistance in a nationally representative adult population. J Clin Hypertens (Greenwich). 2007;9:424-429.
25. SernéEH, DeJongh RT, Eringa EC, et al. Microvascular dysfunction: A potential pathophysiological role in the metabolic syndrome. Hypertension. 2007;50:204-211.
26. Jonk AM, Houben AJHM, DeJongh RT, et al. Microvascular function in obesity: A potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology (Bethesda). 2007;22:252-260.
27. Struijker-Boudier HA, Cohuet GM, Baumann M, et al. The heart, macrocirculation, and microcirculation in hypertension: A unifying hypothesis. J Hypertens Suppl. 2003;21:S19-S23.
28. Rosmond R. Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinology. 2005;30:1-10.
29. Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension. Role of leptin and sympathetic nervous system. Am J Hypertens. 2001;14:103S-115S.
30. Yang R, Barouch LI. Leptin signaling and obesity: Cardiovascular consequences. Circ Res. 2007;101:545-559.
31. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension. 1998;31:409-414.
32. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: Theory and therapy. Hypertension. 2004;43:518-524.
33. Brook RD, Bard RL, Rubenfire M, et al. Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol. 2001;88:1264-1269.
34. Black PH. The inflammatory response is an integral part of the stress response. Implications for atherosclerosis, insulin resistance, type 2 diabetes, and metabolic syndrome X. Brain Behav Immun. 2003;17:350-364.
35. Reaven GM. Insulin resistance, hypertension, and coronary heart disease. J Clin Hypertens (Greenwich). 2003;5:269-274.
36. Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41:625-633.
37. Hall JE. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens. 1997;10:49S-55S.
38. Dessi-Fulgheri P, Sarzani R, Tamburrini P, et al. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J Hypertens. 1997;15:1695-1699.
39. van Harmelen V, Elizalde M, Ariapart P, et al. The association of human adipose angiotensinogen gene expression with abdominal fat distribution in obesity. Int J Obes. 2000;24:673-678.
40. Hall JE, Brands MW, Dixon WN, et al. Obesity-induced hypertension: Renal function and systemic hemodynamics. Hypertension. 1993;22:292-299.
41. Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens. 2007;25:841-848.
42. Fonseca VA. Insulin resistance, diabetes, hypertension, and renin-angiotensin system inhibition: Reducing risk for cardiovascular disease. J Clin Hypertens (Greenwich). 2006;8:713-720.
43. Valensi P, Assayag M, Busby M, et al. Microalbuminuria in obese patients with or without hypertension. Int J Obes Relat Metab Disord. 1996;20:574-579.
44. Sowers JR, Epstein M, Frolich ED. Diabetes, hypertension, and cardiovascular disease: An update. Hypertension. 2001;37:1053-1059.
45. Sharma AM, Engeli S. Managing big issues on lean evidence: Treating obesity hypertension. Nephrol Dial Transplant. 2002;17:353-355.
46. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344:3-10.
47. Appel LJ, Champagne CM, Harsha DW, et al; PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on blood pressure control: Main results of the PREMIER Clinical Trial. JAMA. 2003;289:2083-2093.
48. Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure: A meta-analysis of randomized, controlled trials. Ann Intern Med. 2002;136:493-503.
49. Stevens VJ, Obarzanek E, Cook NR, et al; Trials for the Hypertension Prevention Research Group. Long-term weight loss and changes in blood pressure: Results of the Trials of Hypertension Prevention Phase II. Ann Intern Med. 2001;134(1):1-11.
50. Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: A meta-analysis of randomized controlled trials. Hypertension. 2003;42:878-884.
51. Aucott L, Poobalan A, Smith WCS, et al. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: A systematic review. Hypertension. 2005;45:1035-1041.
52. Blumenthal JA, Sherwood A, Gullette EC, et al. Exercise and weight loss reduce blood pressure in men and women with mild hypertension: Effects on cardiovascular, metabolic, and hemodynamic functioning. Arch Intern Med. 2000;160:1947-1958.
53. Carroll JF, Kyser CK. Exercise training in obesity lowers blood pressure independent of weight change. Med Sci Sports Exerc. 2002;34:596-601.
54. Bakris G, Calhoun D, Egan B, et al; Orlistat and Resistant Hypertension Investigators. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002;20(11):2257-2267.
55. Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens. 2002;20:1873-1878.
56. Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683-2693.
57. Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741-752.
58. Jordan J, Engell S, Redon J, et al. European Society of Hypertension Working Group on Obesity: Background, aims, and perspectives. J Hypertens. 2007;25:897-900.
59. Wofford MR, Anderson DC, Brown CA, et al. Antihypertensive effect of alpha- and beta-adrenergic blockade in lean and obese hypertensive subjects. Am J Hypertens. 2001;14:694-698.
60. Dahlöf B, Devereux RB, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): A randomized trial against atenolol. Lancet. 2002;359:995-1003.
61. Heart Outcome Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE Study and the MICRO HOPE Substudy. Lancet. 2000;255:253-259.
62. Brenner BM, Cooper ME, DeZeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (RENAAL). N Engl J Med. 2001;345:861-869.
63. He J, Ogden LG, Vupputuri S, et al. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. JAMA. 1999;282:2027-2034.
64. Setaro JF. Resistant hypertension. In: Black HR, Elliott W, eds. Clinical Hypertension: A Companion to Braunwald's Heart Disease. Philadelphia, PA: Elsevier/WB Saunders; 2006:498-511.
65. Reaven GM, Clinkingbeard C, Jeppesen J, et al. Comparing the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens. 1995;8:461-466.
66. Reisin E, Weir MR, Falkner B, et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: A multicenter placebo-controlled trial. Treatment of Obese Patients with Hypertension (TROPHY) Study Group. Hypertension. 1997;30:140-145.
67. Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006;29:2592-2597.
68. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of cardvedilol versus metoprolol in patients with Type 2 diabetes mellitus and hypertension. A randomized controlled trial. JAMA. 2004;292:2227-2236.
69. Sarafidis PA. Metabolic syndrome and arterial stiffness. Evidence for gender disparity and early effects of nontraditional risk factors? J Hypertens. 2007;25:935-938.
70. Black HR, Bakris GL, Weber M, et al. Efficacy and safety of darusentan in patients with resistant hypertension: Results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich). 2007;9:760-769.
71. Schinner S, Willenberg HS, Krause D, et al. Adipocytederived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway. Int J Obes (Lond). 2007;31:864-870.
72. Stas S, Whaley-Connell AT, Sowers JR. Aldosterone and hypertension in the cardiometabolic syndrome. J Clin Hypertens (Greenwich). 2008;10:94-96.
73. Sarafidis PA, Whaley-Connell AT, Sowers JR, et al. Cardiometabolic syndrome and chronic kidney disease: What is the link? J Cardiometab Syndr. 2006;1:58-65.
74. Lutsey PL, Steffen LM, Stevens J. Dietary intake and the development of the metabolic syndrome. Circulation. 2008;117:754-761.
75. Brown CD, Higgins M, Donato KA, et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res. 2000;8:605-619.